MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.

MDxHealth 2019 Full Year Results (Audio Only)

MDxHealth’s Corporate Presentation December 2019 (PDF)

MDxHealth 2019 Interim Results for the Half year (Audio Only)

Webcasts & Multimedia

MDxHealth is a molecular diagnostics company that develops and commercializes innovative tests for cancer assessment and the personalized treatments of patients. Utilizing our proprietary, patented DNA methylation platform and biomarkers, we help address the large and growing unmet medical need by offering tests that aid in the improvement of cancer diagnostics, prognosis and treatment.

Share Data


An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides.

Investor Relations Contact

For all investor related questions please call or email:

LifeSci Advisors (IR &PR)

US: +1 646 597 6989